Abivax (ABVX) Invested Capital: 2021-2025
- Abivax's Invested Capital rose 2.45% to $316.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $316.6 million, marking a year-over-year increase of 2.45%. This contributed to the annual value of $341.1 million for FY2024, which is 21.54% down from last year.
- Abivax's Invested Capital amounted to $316.6 million in Q2 2025, which was down 9.31% from $349.1 million recorded in Q1 2025.
- Abivax's 5-year Invested Capital high stood at $434.8 million for Q4 2023, and its period low was $50.8 million during Q4 2022.
- Over the past 3 years, Abivax's median Invested Capital value was $341.1 million (recorded in 2024), while the average stood at $350.1 million.
- Its Invested Capital has fluctuated over the past 5 years, first fell by 27.89% in 2022, then surged by 755.81% in 2023.
- Quarterly analysis of 5 years shows Abivax's Invested Capital stood at $70.5 million in 2021, then fell by 27.89% to $50.8 million in 2022, then spiked by 755.81% to $434.8 million in 2023, then decreased by 21.54% to $341.1 million in 2024, then grew by 2.45% to $316.6 million in 2025.
- Its last three reported values are $316.6 million in Q2 2025, $349.1 million for Q1 2025, and $341.1 million during Q4 2024.
